65,437 trials
Obesity
Primary: Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test — 76; 17 percentage of participants
Overweight · Obesity
Primary: Change in Body Weight (%) — -9.9; -13.4; -1.9 Percentage change — p=<.0001
Migraine
Primary: Change From Baseline in Colonic Transit Time (CTT) at Week 2 — 5.752; -5.348 hours
HIV Infections
Primary: Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) — 4.3; 8.7; 6.7; 29.4 percentage of participants
Excessive Daytime Sleepiness · Cataplexy · Narcolepsy
Primary: Maintenance of Wakefulness Test (MWT) — 10.8; 4.7 minutes — p=<0.001
Dysplasia; Hip · Prosthesis Survival
Primary: Harris Hip Score — 89.8 points
Partial Edentulism
Primary: Change in Stability at 12 Weeks Minus Value at Baseline (Day 1) Comparing Coated and Uncoated Implants Change in Stability From Day 1(Implantation to 12 Weeks After…
Rheumatoid Arthritis
Primary: Total Number of Adverse Events and Serious Adverse Events — 27; 15; 8; 4 count of events
Spinal Cord Injury
Primary: Change From Baseline in Exercise Capacity at 6 Months — 14.6; 18.5; 17.1; 13.9 ml/kg/min
Iron Deficiency Anemia
Primary: Change in Hemoglobin From Baseline to Day 35 — 0.70 g/dL — p=0.1711
Coronavirus Infections
Primary: Measurement of the Change in Oxygen Requirement From Baseline — -38.8; -33.0 L/min*day
Alpha1-Antitrypsin Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4 Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 12; 11; 15; 8 Participants
Attention Deficit Hyperactivity Disorder · Adherence, Medication
Primary: Proportion of Days Covered With Medicine — 0.24; 0 proportion of days covered with medicine — p=0.08
Peripheral Artery Disease · Type 2 Diabetes
Primary: Mean Change in Low Shear Blood Viscosity — 1.045; -1.793; -1.759 5 s^-1 cPs